An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
VERDICT
The label
Markup
read at $477.36
Vertex Pharmaceuticals holds its Markup at $477.36.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-24
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 34 days
Price
$477.36
Valuation
28.35 trailing · 22.40 forward price to earnings
Values screen
PASS· score 71.4
Beta
0.29
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads OVERVALUED — it trades at roughly a 9% discount to our $519.46 fair value, strong competitive moat, 7.80% revenue growth.
Read at
$477.36
28.35 P/E · 22.40 fwd
Our fair value
$519.46
9% discount
Analyst target (avg)
$570.00
+19% to current
Target low $350.00Analyst target rangeTarget high $652.00
▲ current $477.36 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$477.36
you are here
Conservative
$351.69
-26%
Analyst avg
$570.00
+19%
Our fair value
$519.46
+9%
Analyst high
$652.00
+37%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
7.80%
Profit margin
35.51%
Debt to equity
10.26
Analyst consensus
Buy · 23 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 7.9% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 22.3% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 27.8% of assets, under the 49% limit.Pass
Revenue purityOnly 4.1% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Cystic Fibrosis Drugs Built a Biotech Leader
Picture a firm that turned a once-fatal lung disease into a treatable condition for thousands of patients. Vertex has done exactly that with its cystic fibrosis medicines and now posts a 36 percent profit margin, 24 percent return on equity and a strong moat in specialty biotech.
The numbers show real quality. Revenue still rises 8 percent a year, the ethical screen clears without issue and 23 analysts rate the shares a buy. Yet our fair value sits only 7 percent above the current price, leaving the stock overvalued on a 22.7 times forward earnings multiple.
That thin margin of safety is the real concern. Any slip in growth or fresh competition could close the gap quickly and push the shares lower. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
VRTX trades on a US exchange. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (29 analysts) rates it buy, with a mean price target of $548. It reported earnings in this window, a natural checkpoint for the thesis. Entered 2026-07-28 · Accumulation
JOURNAL
The dated journal · newest first, never edited
2026-07-28Accumulation$477.36+0.0%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (29 analysts) rates it buy, with a mean price target of $548. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-27Accumulation$477.36+6.8%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (29 analysts) rates it buy, with a mean price target of $548. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Accumulation$446.83+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (29 analysts) rates it buy, with a mean price target of $548.
2026-07-03Accumulation$446.83+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (71). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$446.83Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (71). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.